MX2015010967A - Formulaciones transdermicas de laquinimod. - Google Patents

Formulaciones transdermicas de laquinimod.

Info

Publication number
MX2015010967A
MX2015010967A MX2015010967A MX2015010967A MX2015010967A MX 2015010967 A MX2015010967 A MX 2015010967A MX 2015010967 A MX2015010967 A MX 2015010967A MX 2015010967 A MX2015010967 A MX 2015010967A MX 2015010967 A MX2015010967 A MX 2015010967A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
laquinimod
optionally
transdermal patch
provides
Prior art date
Application number
MX2015010967A
Other languages
English (en)
Inventor
Dirk Schenk
Ralph Stefan
Tanja Pries
Hans-Juergen Mika
Sabine Prohl
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2015010967A publication Critical patent/MX2015010967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención proporciona un parche transdérmico que comprende: a) una capa de respaldo; b) un revestimiento; c) opcionalmente, una membrana altamente porosa; y d) una composición farmacéutica que comprende: (i) opcionalmente, un adhesivo sensible a la presión en una cantidad de hasta aproximadamente 95% de peso de la composición farmacéutica, (ii) el laquinimod en una cantidad de aproximadamente 0.1-20% de peso de la composición farmacéutica, y (iii) opcionalmente, uno o más potenciadores de permeación en una cantidad total de hasta aproximadamente 70% de peso de la composición farmacéutica. Esta invención también proporciona un método para suministrar el laquinimod a través de la piel de un sujeto y para tratar a un sujeto humano afligido con una forma de esclerosis múltiple que comprende la administración de un parche transdérmico a la piel del sujeto como se describe en la presente. Esta invención además proporciona un parche transdérmico como se describe en la presente para usarse en un tratamiento de un sujeto humano afligido con una forma de esclerosis múltiple.
MX2015010967A 2013-03-14 2014-03-13 Formulaciones transdermicas de laquinimod. MX2015010967A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781585P 2013-03-14 2013-03-14
PCT/US2014/026807 WO2014152009A1 (en) 2013-03-14 2014-03-13 Transdermal formulations of laquinimod

Publications (1)

Publication Number Publication Date
MX2015010967A true MX2015010967A (es) 2015-10-26

Family

ID=50729775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010967A MX2015010967A (es) 2013-03-14 2014-03-13 Formulaciones transdermicas de laquinimod.

Country Status (8)

Country Link
US (1) US20160038435A1 (es)
EP (1) EP2968203A1 (es)
JP (1) JP2016513665A (es)
CA (1) CA2900977A1 (es)
HK (1) HK1220125A1 (es)
IL (1) IL240557A0 (es)
MX (1) MX2015010967A (es)
WO (1) WO2014152009A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2015138887A1 (en) * 2014-03-14 2015-09-17 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of laquinimod by oral patches

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
BRPI0617477A2 (pt) 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
EP2035001B1 (en) 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
BRPI0913518A2 (pt) 2008-09-03 2016-07-26 Teva Pharma composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune
MX2011013902A (es) 2009-06-19 2012-02-23 Teva Pharma Tratamiento de esclerosis multiple con laquinimod.
ME02414B (me) 2009-07-30 2016-09-20 Teva Pharma Tretman kronove bolesti lakvinimodom
EP3064206B1 (en) 2009-08-10 2019-03-20 Active Biotech AB Treatment of huntington's disease using laquinimod
DE102010026879A1 (de) * 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
JP5819328B2 (ja) 2010-03-03 2015-11-24 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療
PT2542080T (pt) 2010-03-03 2016-11-16 Teva Pharma Tratamento de artrite causada por lúpus usando laquinimod
US8252993B1 (en) 2010-05-25 2012-08-28 Pioneer Hi-Bred International, Inc. Inbred maize variety PH18FN
AU2011274502A1 (en) 2010-07-09 2013-02-28 Teva Pharmaceutical Industries Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
SG10201505236YA (en) 2010-07-09 2015-08-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2012078591A1 (en) 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Also Published As

Publication number Publication date
IL240557A0 (en) 2015-10-29
US20160038435A1 (en) 2016-02-11
CA2900977A1 (en) 2014-09-25
WO2014152009A1 (en) 2014-09-25
HK1220125A1 (zh) 2017-04-28
JP2016513665A (ja) 2016-05-16
EP2968203A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
PH12015502550A1 (en) Transdermal delivery system
MX366560B (es) Parche adhesivo con composicion antimicrobiana.
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
NZ705743A (en) Compositions and methods for treating cutaneous scarring
MX2016008138A (es) Sistema para el suministro transdermico de ingredientes activos.
CY1116638T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
PH12015501169A1 (en) Transdermal delivery system
PH12015502280A1 (en) Transdermal delivery system comprising donepezil or its salt
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
MX2018009575A (es) Sistema y metodo para conservar y suministrar un gas terapeutico a una herida.
WO2015023649A3 (en) Peptides for enhancing transdermal delivery
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
MX2015010967A (es) Formulaciones transdermicas de laquinimod.
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
MY184693A (en) Bilayer hydrocolloid films containing therapeutic agents
EA201792165A1 (ru) Устройство для ухода за полостью рта
PH12016501500B1 (en) Topical formulations of heparin
BR112014018426A8 (pt) Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina
MY162768A (en) Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
MY197404A (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
MX2017005046A (es) Metodo y articulos para inhibir las contracciones vesicales.
BR112016006842A2 (pt) dispositivos de distribuição transdérmica de dexme-detomidina e métodos de uso dos mesmos
IN2013DE03033A (es)